Yes Bank building. (File photo | EPS) 
Business

Yes Bank shares gain nearly 4 per cent after Moody's ratings upgrade

Moody's Investors Service on Monday said it has upgraded Yes Bank's long-term foreign currency issuer rating by a notch to 'B3' from 'Caa1' after a Rs 15,000-crore capital raising.

From our online archive

NEW DELHI: Shares of Yes Bank on Tuesday gained nearly 4 per cent after Moody's Investors Service said it has upgraded the company's long-term foreign currency issuer rating by a notch.

The stock rose by 3.58 per cent to Rs 12.41 on the BSE. On the NSE, it gained 3.33 per cent to Rs 12.40.

Moody's Investors Service on Monday said it has upgraded Yes Bank's long-term foreign currency issuer rating by a notch to 'B3' from 'Caa1' after a Rs 15,000-crore capital raising.

Despite the upgrade, Yes Bank still remains under non-investment grade. Obligations rated 'B' are considered speculative and are subject to high credit risk, while those rated 'Caa' are judged to be speculative of poor standing and are subject to very high credit risk.

"Moody's has upgraded the bank's long-term foreign and local currency bank deposit ratings to B3 from Caa1, and its foreign currency senior unsecured MTN (medium-term note) programme rating to (P)B3 from (P)Caa1," it said.

Giving rationale for rating action, the rating agency said Yes Bank's successful equity capital raise of Rs 15,000 crore (about USD 2 billion) has bolstered its solvency and is the main driver of the ratings upgrade.

The successful equity raising showcases Yes Bank's regained access to external market funds, which is a result of its improving financial strength and will support depositor confidence, it said.

Is October 2026 a harbinger of May 2028?

DVAC raids 25 locations in TN linked to KN Nehru in cash-for-jobs scam probe; Stalin cries foul

Stop sermonising others; introspect over BJP's Varanasi losses, Congress tells PM Modi

DPDP Act does not curtail freedom of press, but open to amend law: Govt

Now, pay over 90 per cent less for some cancer meds